Europe Blood Screening Market

Europe Blood Screening Market Size (2023 to 2028)

According to the report, the Europe Blood Screening Market size is valued at USD 0.57 billion in 2023 and is expected to reach USD 0.88 billion by 2028, growing at a CAGR of 9.1% during the forecast period.

The factors contributing to market growth for the blood screening market in European countries are aware of blood donation drives and safe procedures, and quality assurance systems. European countries made blood screening procedures compulsory for various diseases like HIV, Cancers, HBV, and HSV. An increase in diseases and irresistible infections is anticipated to enlarge the market advancement in the coming years. Rigid government guidelines concerning the screening are considered and executed in action. Tolerant security is foreseen to push market development additionally. The ascent in the quantity of complex medical procedures performed, such as chemotherapy, heart medical procedure, and organ relocate, which require an enormous number of blood tests, is likewise prone to positively affect the market.

Along with the market growth factors, the blood screening market has to undergo some restraints which held back the market’s growth. European countries are considered developing countries, and hence the rise in population is also observed. The more the population, means more the spread of infection rate. Therefore, infection control through blood transfusion procedures is not possible, and this is to be regulated and controlled. And there are strict regulation bodies to provide approval, and this hampers the market growth. The blood screening market needs a lot of workforce in various divisions, and the lack of skilled persons also holds back the market growth. The European nation is a technologically developed region where alternative techniques for blood screening are on demand. It hampers the market growth.

Covid-19 Impact on the market:

Due to COVID lockdown and travel ban issues, there’s a significant impact on lab tests being performed for patients. Also, there’s a lot of loss in skilled staff and human resources, which impacted groundwork. It has been difficult for people who cannot get access to clinics or diagnostic centers. The exports and imports of materials, goods, and devices required for the market have been halted. The loss of pay is considerably noted for the staff and health workers in the market.

This research report on the Europe Blood Screening Market has been segmented and sub-segmented into the following categories:

By Technology: 

• Nucleic Acid Amplification
• Elisa
• Rapid Test
• NGS
• Western Blotting

By Product: 

• Instrument
• Reagent & Kits
• Software

By End User: 

• Blood banks
• Hospital

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European blood screening market was the second largest in the global market in 2022. European nations have made it compulsory for every citizen for blood screening for HIV, HBV, HCV, parvovirus 19, and different infections. The blood screening administrations in Germany are directed by the International Red Cross, the Code of International Society of Blood Transfusion, and the German Transfusion Act. In France, the French Blood Establishment (EFS) directs the assortment, planning, testing, and circulation of labile blood items. 

Whereas in Italy, the National Blood Center (NBC), a well-being service division, regulates the coordination of specialized and logical control of the blood framework.

Prominent Companies dominating the Europe Blood Screening Market Profiled in the Report are Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Ortho Clinical Diagnostics, Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche Ltd, Grifols, Siemens AG, and Beckman Coulter, Inc.